Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.12
- Piotroski Score 4.00
- Grade Buy
- Symbol (CUE)
- Company Cue Biopharma, Inc.
- Price $1.72
- Changes Percentage (15.44%)
- Change $0.23
- Day Low $1.32
- Day High $1.74
- Year High $3.25
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $7.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.07
- Trailing P/E Ratio -1.38
- Forward P/E Ratio -1.38
- P/E Growth -1.38
- Net Income $-50,733,000
Income Statement
Quarterly
Annual
Latest News of CUE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Student rescues cat and spends $30 on toys, she eats his homework instead
A student's rescue cat ate their homework, prompting a classic excuse. The story dates back over a century, evolving into a common excuse for missed deadlines. Despite the mishap, the student was gran...
By Newsweek | 1 day ago -
What Are the Sun Belt, Rust Belt and Barbecue Belt? Trying to Define America's Regions.
America is a diverse patchwork of regions like the Rust Belt, Sun Belt, and Bible Belt, each with unique characteristics and voting patterns. These regional distinctions play a significant role in ele...
By The New York Times | 1 day ago -
Illinois man rescued after bridge collapse causes tractor to trap him in creek
Seattle police dramatically save man from train tracks as a train approaches. In Illinois, firefighters rescue man trapped under a tractor in a creek after a bridge collapse, taking him to the hospita...
By Fox News | 1 day ago
